- Post-doc; PhD, Msc
- +47 22 78 23 18
2016 – Present: Ph.D student in Department of Cellular Therapy, Oslo University Hospital, Norway
2014 – 2016 M.Sc. in Molecular Bilogy and Genetics, Bilkent University, Ankara, Turkey
2010 – 2014 B.Sc. in Molecular Bilogy and Genetics, Bilkent University, Ankara, Turkey
- Therapeutic TCRs
- Checkpoint Inhibitors
- Chimeric Antigen Receptors (CAR)
- Cloning, expression and functional tests
2016 (Oct) – Present Research Member, Ph.D. candidate at Department of Cellular Therapy, OUS Radiumhospitalet, Oslo, NORWAY
2014-2016 Research Member, M.Sc. candidate at THORLAB. Memory-like T cells transduced with tumor-specific epitope elicited pronounced cytotoxic potential. Ihsan Dogramaci Bilkent University, Molecular Biology and Genetics Department, Ankara, TURKEY.
2013-2014 Fall Senior student at Prof. Ihsan Gursel Group. Cloning of TLR-9 and its interaction with different ligands. Ihsan Dogramaci Bilkent University, Molecular Biology and Genetics Department, Ankara, TURKEY.
June-Sept. 2013 Intern at Prof. Leo Joosten and Prof. Mihai Netea Group. ERASMUS Summer Internship Scholarship. NOD-like receptor protein-12 (NLRP12) gene polymorphism G39V in inflammatory bowel disease and Olecranon Bursitis patients` immune responses to Pseudallescheria boydii infection. Nijmegen Institute for Infection, Inflammation & Immunity, Nijmegen, NETHERLANDS.
2012-2013 Intern at Prof. Ihsan Gursel Group. Ihsan Dogramaci Bilkent University, Molecular Biology and Genetics Department, Ankara, TURKEY.
2010-2012 Intern at Assist. Prof. Ebru Erbay Group. TUBITAK 2209 project. Discovery of potential substrates of PKR via chemical genetic methods. Ihsan Dogramaci Bilkent University, Molecular Biology and Genetics Department, Ankara, TURKEY.
Protective Loop Ileostomy Closure Techniques: Comparison of Three Different Surgical Techniques
Cureus, 12 (10), e10977
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther (in press)
Colorectal cysts as a validating tool for CAR therapy
BMC Biotechnol, 20 (1), 30
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Cancer Immunol Res, 7 (3), 355-362
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
Treating osteosarcoma with CAR T cells
Scand J Immunol, 89 (3), e12741
A Spheroid Killing Assay by CAR T Cells
J Vis Exp (142)
Fishing therapeutic T-cell receptors in healthy donor blood, is safety predictable?
Transl. Cancer Res., 6 3, S622-S624
A TCR-based Chimeric Antigen Receptor
Sci Rep, 7 (1), 10713